academic article

• A pilot randomized control trial to evaluate pelvic floor muscle training for urinary incontinence among gynecologic cancer survivors..  Gynecologic oncology.  132:154-158. 2014
• High-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile: a double-blind, randomized controlled clinical trial..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  57:943-951. 2013
• A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies..  Cancer chemotherapy and pharmacology.  69:547-554. 2012
• Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen..  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.  53:1188-1195. 2011
• Incidence rate for hantavirus infections without pulmonary syndrome, Panama..  Emerging infectious diseases.  17:1936-1939. 2011
• Organ-wide telomeric status in diseased and disease-free prostatic tissues..  The Prostate.  70:1471-1479. 2010
• GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer..  Breast cancer research and treatment.  123:51-58. 2010
• Tumor MET expression may not predict the risk of venous thromboembolism in cancer patients..  Oncology research.  19:93-97. 2010
• GPR30 predicts poor survival for ovarian cancer..  Gynecologic oncology.  114:465-471. 2009
• Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in chile..  The Journal of infectious diseases.  195:1563-1571. 2007
• Overexpression of a dominant-negative allele of YPT1 inhibits growth and aspartyl protease secretion in Candida albicans..  Microbiology (Reading, England).  147:1961-1970. 2001
• Mental illness: is there an association with cancer screening among women veterans?.  Women's health issues : official publication of the Jacobs Institute of Women's Health.  21:S195-S202.
• Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols..  Urologic oncology.  26:610-615.